A cost effectiveness analysis of natalizumab vs. interferon-beta and glatiramer acetate in patients with active relapsing-remitting multiple sclerosis currently failing on existing therapy.
Poster presentation PND13 - 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
Authors: Gani R, Samuels ER, Hughes S, Giovanonni G.
Year: 2008
Category: test1